Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 10/20 | 0.44 |
| ▸ | RXRA | P19793 | 9/20 | 0.44 |
| ▸ | RXRG | P48443 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104677 | 0.89 | GABRB2 (0.52) | GABRA1GABRB2MAPTKDM4EGAA | |
| SCHEMBL22861023 | 0.89 | GABRB2 (0.52) | GABRA1GABRB2MAPTKDM4EGAA | |
| SCHEMBL15077166 | 0.87 | GABRB2 (0.46) | GABRA1GABRB2MAPTKDM4EGAA | |
| SCHEMBL26230931 | 0.87 | GABRA1 (0.55) | GABRA1GABRB2RXRBRXRARXRG | |
| SCHEMBL13866628 | 0.87 | RXRA (0.52) | RXRBRXRARXRGMAPTKIF11 | |
| SCHEMBL14075750 | 0.84 | RXRA (0.53) | RXRBRXRARXRGKIF11 | |
| SCHEMBL9482063 | 0.84 | RXRA (0.54) | RXRBRXRARXRGMAPTKIF11 | |
| SCHEMBL4572745 | 0.84 | GABRA1 (0.58) | GABRA1GABRB2RXRBRXRARXRG | |
| SCHEMBL3439602 | 0.80 | RAPGEF4 (0.48) | GABRA1GABRB2RXRBRXRAMAPT | |
| SCHEMBL1754077 | 0.80 | GABRA1 (0.44) | GABRA1GABRB2RXRBRXRARXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10836761-B2 | Cinchonine-derived catalysts and methods of using same | BRANDEIS UNIVERSITY (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200048243-A1 | CINCHONINE-DERIVED CATALYSTS AND METHODS OF USING SAME | BRANDEIS UNIVERSITY (US) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836761-B2 | Cinchonine-derived catalysts and methods of using same | MCM2, MCM7, MCM5 | GABRA1 4625/4885GABRB2 4503/4885RXRB 4555/4885 |
| US-20200048243-A1 | CINCHONINE-DERIVED CATALYSTS AND METHODS OF USING SAME | MCM2, MCM7, MCM5 | GABRA1 4625/4885GABRB2 4503/4885RXRB 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.